Special Issue "New Advances in Dyslipidemia"
Deadline for manuscript submissions: closed (20 August 2023) | Viewed by 30614
More than 50 years ago, the Framingham Heart Study and other major epidemiologic studies identified total cholesterol, and later low-density lipoprotein-cholesterol (and inversely, high-density lipoprotein-cholesterol) as important risk factors for ASCVD. More recently, lipoprotein(a) has been confirmed as a genetic risk factor for ASCVD. While statin therapies have become the standard of care in the past quarter century, the advent of newer non-statin therapies offers a significant opportunity to address residual ASCVD risk beyond statin therapy.
Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). However, despite current traditional therapies (e.g., statins), significant residual risk for ASCVD risk remains, warranting the need to better understand newer therapeutic options for reducing such risk. This Special Issue will address newer concepts in the evaluation and management of dyslipidemia, including the rationale for newer goals in lipid treatment given recent international guidelines, global trends in the epidemiology of dyslipidemia, newer concepts and therapies in the evaluation and management of familial hypercholesterolemia, newer therapies for LDL-C lowering beyond statin therapy, the status of lipoprotein(a) as a causal risk factor and newer therapeutic approaches to address it, the evaluation and management of dyslipidemia in children, newer and emerging therapies for hypertriglyceridemia, and nutraceuticals to address dyslipidemia in COVID-19 patients.
This Special Issue will discuss the latest clinical trials and other research developments regarding newer and emerging therapies for the management of dyslipidemia to reduce ASCVD residual risk. The hope is to provide clinicians with the latest information on key aspects of the evaluation and treatment of dyslipidemia, including newer non-statin approaches for reducing ASCVD residual risk, such as settings of elevated LDL-C, lipoprotein(a), and familial hypercholesterolemia.
We are seeking papers on novel topics that help advance the evaluation and management of different aspects of dyslipidemia.
Prof. Dr. Nathan D. Wong
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cardiovascular disease
- risk factors